Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price
Bristol Myers Squibb plans to launch its schizophrenia drug, Cobenfy, in the UK in 2026 at an annual price of $22,500, matching the US list price1234.
Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of the traditional dopamine receptors, representing a major shift in schizophrenia treatment13.
The planned UK launch will proceed after Bristol Myers submits a marketing authorization application to UK regulators later in 2025, using a fast-track route13.
Bristol Myers has warned that it may withdraw the UK launch if NICE and the NHS do not adequately recognize the drug's value during pricing negotiations1.
Cobenfy received US FDA approval in 2024 and is branded as xanomeline/trospium chloride34.
Sources:
1. https://trial.medpath.com/news/63ac44bb849a7de4/bristol-myers-squibb-plans-2026-uk-launch-of-breakthrough-schizophrenia-drug-cobenfy-at-22500-annual-price
2. https://www.tradingview.com/news/reuters.com,2025:newsml_L3N3V90RT:0-bristol-myers-plans-to-launch-schizophrenia-drug-in-uk-at-list-price-equal-to-the-us/
3. https://kfgo.com/2025/09/22/bristol-myers-plans-uk-launch-of-schizophrenia-drug-in-2026/